Passage Bio Q2 net loss narrows 16.67% to $7.82 million

Reuters2026/08/10 11:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Passage Bio posted a net loss of $7.82 million, narrowing from $9.39 million a year earlier; operating loss improved to $8.27 million.
R&D expense fell 42.51% to $3.34 million; general and administrative costs rose 52.06% to $6.87 million.
Other income dropped 52.48% to $451,000; results included a $1.94 million net gain on lease terminations.
Cash and cash equivalents totaled $24.2 million as of June 30, 2026, with management flagging substantial doubt about going-concern status.
Company is winding down gene-therapy programs, terminated key Catalent and Gemma arrangements, and expects its Remix merger to close in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-093021), on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Passage Bio Q2 net loss narrows 16.67% to $7.82 million

You may also like

Crypto prices